- In April 2024, GlaxoSmithKline (GSK) launched a new line of medicated lip care products enriched with antifungal and antibacterial agents specifically designed to treat symptoms of angular cheilitis. The formulation combines therapeutic efficacy with cosmetic appeal, catering to growing consumer demand for multi-functional lip care. This product expansion highlights GSK’s commitment to addressing both medical and consumer health needs within the dermatology segment
- In March 2024, Pfizer Inc. initiated a clinical trial investigating the use of low-dose topical corticosteroids in combination with antifungal therapy for persistent angular cheilitis. The study aims to assess the safety and efficacy of dual-action treatment in chronic or recurrent cases, particularly among immunocompromised patients. This research underscores Pfizer’s investment in evidence-based, combination therapies that offer targeted relief and long-term management of skin-related conditions
- In February 2024, Himalaya Wellness, a leading natural health product manufacturer, introduced an herbal-based angular cheilitis cream formulated with neem, turmeric, and aloe vera extracts. The product targets inflammation, microbial growth, and healing simultaneously, offering a plant-based alternative for mild to moderate cases. This development reflects the increasing consumer shift toward natural and ayurvedic options in dermatological care
- In January 2024, Johnson & Johnson Consumer Health enhanced its Neosporin lip treatment line with a new formulation containing added vitamins B2 and B12 to support recovery in patients experiencing angular cheilitis due to nutritional deficiencies. The innovation aligns with the rising trend of integrating nutritional support into topical dermatological therapies, emphasizing a holistic approach to skin healing
- In December 2023, Dr. Reddy’s Laboratories partnered with leading dermatology clinics across Southeast Asia to distribute prescription-grade antifungal and antibacterial treatments for angular cheilitis. This strategic move aims to improve treatment accessibility in emerging markets, addressing unmet needs where over-the-counter options are limited. The initiative highlights the company’s regional expansion and focus on skin infection management through clinically backed solutions
